Tissue-specific microRNA expression alters cancer susceptibility conferred by a TP53 noncoding variant

Area of Science:

• Genetics
• Oncology
• Molecular Biology

Background:

• A noncoding polymorphism (rs78378222) in the TP53 gene is linked to brain tumors.
• This common variant affects millions globally, suggesting a significant role in cancer predisposition.

Purpose of the Study:

• To investigate the association of the TP53 variant (rs78378222) with soft tissue sarcoma and breast cancer.
• To elucidate the underlying molecular mechanisms by which this variant influences tumorigenesis in different tissues.

Main Methods:

• Association study of the TP53 variant with cancer incidence.
• Generation of a genetically modified mouse model carrying the variant.
• Analysis of microRNA binding sites and p53 expression in different tissues.

Main Results:

• The TP53 variant (rs78378222) is positively associated with soft tissue sarcoma risk.
• Conversely, the variant demonstrates a protective effect against breast cancer.
• Mouse models showed accelerated tumorigenesis in the brain but delayed mammary tumor development.
• The variant alters microRNA (miR-382-5p and miR-325-3p) targeting, leading to differential p53 expression in brain and mammary gland.

Conclusions:

• The TP53 variant rs78378222 exhibits tissue-specific effects on cancer susceptibility, contrasting with Li-Fraumeni Syndrome.
• MicroRNA-mediated regulation of p53 expression by genetic variants is a key mechanism in cancer development.
• This study highlights the complex interplay between genetic variation, microRNA expression, and cancer risk.